Cargando…

Overall survival of prostate cancer from Sangrur and Mansa cancer registries of Punjab state, India

INTRODUCTION: There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India. METHODS: In the year 2013–2016, a total of 171 pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Budukh, Atul Madhukar, Thakur, Jarnail S., Dora, Tapas Kumar, Kadam, Prithviraj R., Bagal, Sonali S., Patel, Kamalesh Kumar, Goel, Alok K., Sancheti, Sankalp M., Gulia, Ashish R., Chaturvedi, Pankaj P., Dikshit, Rajesh P., Badwe, Rajendra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249534/
https://www.ncbi.nlm.nih.gov/pubmed/37304993
http://dx.doi.org/10.4103/iju.iju_38_23
Descripción
Sumario:INTRODUCTION: There is a scarcity of population-based prostate cancer survival data in India. We assessed the population-based, overall survival of patients with prostate cancer from the Sangrur and Mansa cancer registries of the Punjab state, India. METHODS: In the year 2013–2016, a total of 171 prostate cancer cases were registered in these two registries. Based on these registries, survival analysis was performed using the date of diagnosis as the starting date and the last follow-up date being December 31, 2021 or the date of death. Survival was calculated using STATA software. Relative survival was calculated using the Pohar Perme method. RESULTS: Follow up was available for all the registered cases. Of the 171 cases, 41 (24%) were alive and 130 (76.0%) were dead. Of the prescribed treatments, 106 (62.7%) cases completed the treatment and 63 (37.3%) cases did not complete the treatment. Overall, 5-year age-standardized prostate cancer relative survival was 30.3%. Patients who completed the treatment had a 7.8 times higher 5-year relative survival (45.5%) compared to those who did not (5.8%). The difference between the two groups is statistically significant (hazard ratio 0.16, 95% confidence interval [0.10–0.27]). CONCLUSION: To improve survival, we need to raise awareness in the community and among primary physicians so that prostate cancer cases can reach the hospital early and should be treated effectively. The cancer center should develop the systems in their hospital so that there will be no hurdles to the patients in treatment completion. We found a low overall relative survival among patients of prostate cancer in these two registries. Patients who received treatment had a significantly higher survival.